ReNeuron has negotiated a Supplemental Terms Agreement with potential to generate revenue of up to £6m
01 July 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, is pleased to announce that it has negotiated and signed a Supplemental Terms Agreement with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK) which has the potential to generate revenues of up to £6m for the Company.